In this online CME self-learning program:
Colorectal cancer (CRC) is the third-leading cause of cancer deaths in the U.S. While a majority of patients are diagnosed before their disease has metastasized, a fifth of patients have advanced disease at the time of diagnosis. Early detection and screening have been shown to significantly reduce CRC mortality, and screening is widely recommended for average-risk adults beginning at age 50 years, (as well as earlier for individuals at higher risk). Since the mid-1990s, the U.S. Preventive Services Task Force, American Cancer Society, and other groups have recommended several modalities for screening: fecal occult blood testing (FOBT), flexible sigmoidoscopy, colonoscopy, and barium enema. Recent years have seen the addition of newer screening technologies, including stool DNA, computed tomographic colonography, and capsule endoscopy.
Healthcare professionals including: medical oncologists, primary care physicians, pathologists, gastroenterologists, and managed care medical care directors; physicians assistants, nurse practitioners, nurses, and pharmacists specializing in oncology; and other clinicians who are involved in providing diagnostic and therapeutic services for patients with CRC.
This program is supported by educational grants from AMGEN.
Learners may participate in this activity free of charge.
Release Date: December 11, 2020 -- Expiration Date: December 11, 2022
Faculty: George Fisher, MD, PhD
Faculty member introduction, disclosures, overview of colorectal
Major findings from ASCO 2020, including clinical trial data relevant
to both community and health-system practice and recognized
barriers to implementing those findings in practice
By the end of the session the participant will be able to:
ACCME Activity #201540534ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: George Fisher MD, PhD, Stanford University, has received consulting honoraria from Merck, Terumo, Avanced Accelerator Applications. He has also received research/data safety grant support from AstraZeneca, Silensee, Roche/Genetech, Adurono, and Fourty-seven.
Disclosures of Educational Planners: Charles Turck, PharmD has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by educational grants from AMGEN.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.